TW200733965A - Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea - Google Patents
Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-ureaInfo
- Publication number
- TW200733965A TW200733965A TW095145947A TW95145947A TW200733965A TW 200733965 A TW200733965 A TW 200733965A TW 095145947 A TW095145947 A TW 095145947A TW 95145947 A TW95145947 A TW 95145947A TW 200733965 A TW200733965 A TW 200733965A
- Authority
- TW
- Taiwan
- Prior art keywords
- phenyl
- pyrrolo
- prodrugs
- dichloro
- pyrimidine
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- VFCRSIORGUNNGT-UHFFFAOYSA-N 1-[5-(4-amino-7-propan-2-ylpyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxyphenyl]-3-(2,4-dichlorophenyl)urea Chemical compound COC1=CC=C(C(=O)C=2C3=C(N)N=CN=C3N(C(C)C)C=2)C=C1NC(=O)NC1=CC=C(Cl)C=C1Cl VFCRSIORGUNNGT-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74907005P | 2005-12-09 | 2005-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200733965A true TW200733965A (en) | 2007-09-16 |
Family
ID=38123252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095145947A TW200733965A (en) | 2005-12-09 | 2006-12-08 | Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea |
Country Status (8)
| Country | Link |
|---|---|
| AR (1) | AR058293A1 (fr) |
| DO (1) | DOP2006000271A (fr) |
| GT (1) | GT200600496A (fr) |
| NL (1) | NL2000337A1 (fr) |
| PE (1) | PE20071037A1 (fr) |
| TW (1) | TW200733965A (fr) |
| UY (1) | UY29991A1 (fr) |
| WO (1) | WO2007066189A2 (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008313622A1 (en) * | 2007-10-19 | 2009-04-23 | Abbott Gmbh & Co. Kg | Solid dispersion product of N-aryl urea-based drugs |
| CA2699335A1 (fr) * | 2007-10-19 | 2009-04-23 | Abbott Gmbh & Co. Kg. | Produit de dispersion solide contenant un compose n-aryle a base d'uree |
| US8697709B2 (en) * | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| EP2519525A4 (fr) | 2009-12-30 | 2013-06-12 | Arqule Inc | Composés de pyrroloaminopyrimidine substitués |
| ES2676209T3 (es) * | 2010-06-23 | 2018-07-17 | Metabolex Inc. | Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina |
| WO2012088266A2 (fr) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3 |
| MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
| US20140004192A1 (en) * | 2012-04-13 | 2014-01-02 | Ziopharm Oncology, Inc. | Pharmaceutical formulations of indibulin and uses thereof |
| UA125503C2 (uk) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| AU2013323426A1 (en) | 2012-09-26 | 2015-04-23 | The Regents Of The University Of California | Modulation of ire1 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CN107722012B (zh) * | 2016-08-11 | 2020-05-29 | 斯福瑞（南通）制药有限公司 | 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (fr) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| WO2021146424A1 (fr) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| CA3220155A1 (fr) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Heterocycles tricycliques utiles en tant qu'inhibiteurs de fgfr |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| JP2025015449A (ja) * | 2023-07-18 | 2025-01-30 | 信越化学工業株式会社 | 固体分散体用組成物、固体分散体及び固体分散体の製造方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE364374T1 (de) * | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| UA80171C2 (en) * | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
-
2006
- 2006-11-24 WO PCT/IB2006/003416 patent/WO2007066189A2/fr not_active Ceased
- 2006-11-27 NL NL2000337A patent/NL2000337A1/nl active Search and Examination
- 2006-12-05 DO DO2006000271A patent/DOP2006000271A/es unknown
- 2006-12-06 PE PE2006001565A patent/PE20071037A1/es not_active Application Discontinuation
- 2006-12-06 UY UY29991A patent/UY29991A1/es not_active Application Discontinuation
- 2006-12-07 GT GT200600496A patent/GT200600496A/es unknown
- 2006-12-07 AR ARP060105422A patent/AR058293A1/es unknown
- 2006-12-08 TW TW095145947A patent/TW200733965A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007066189A2 (fr) | 2007-06-14 |
| AR058293A1 (es) | 2008-01-30 |
| PE20071037A1 (es) | 2007-11-19 |
| NL2000337A1 (nl) | 2007-06-12 |
| GT200600496A (es) | 2007-07-17 |
| UY29991A1 (es) | 2007-07-31 |
| WO2007066189A3 (fr) | 2008-08-14 |
| DOP2006000271A (es) | 2007-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200733965A (en) | Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea | |
| CA2510853A1 (fr) | Derives de pyrrolopyrimidine | |
| MXPA06002296A (es) | Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. | |
| GEP20115174B (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| WO2007138472A3 (fr) | Dérivés de la triazolopyridazine | |
| DE60329001D1 (en) | 8-hydroxychinolinderivate | |
| TW200728307A (en) | Novel spirochromanone derivatives | |
| GEP20084439B (en) | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof | |
| UA91129C2 (ru) | Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит | |
| TNSN07384A1 (en) | Spiroheterocyclic compounds and their uses as therapeutic agents | |
| MXPA02012034A (es) | Derivados de tiofeno utiles como agentes anticancerosos. | |
| GEP20105134B (en) | Agents for preventing and treating disorders involving modulation of the ryr receptors | |
| WO2004020431A3 (fr) | Nouveaux dérivées de benzoimidazole utilisés en tant qu'agents antiprolifératifs | |
| WO2008020040A3 (fr) | Utilisation de composés et de dérivés de 2,5-dihydroxybenzène pour le traitement de la fibrose | |
| MY151003A (en) | Stable pharmaceutical composition comprising a pyrimidine-sulfamide | |
| WO2003074529A3 (fr) | Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation | |
| TW200728260A (en) | Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof | |
| TW200612936A (en) | Indole derivatives | |
| WO2007146856A3 (fr) | Gamma lactames substitués utilisés en tant qu'agents thérapeutiques | |
| TW200626158A (en) | Naphthaline derivatives | |
| MX2009007038A (es) | Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales. | |
| MX2008012093A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos. | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| WO2005007642A3 (fr) | Nouveaux amides utilises dans le traitement de la douleur | |
| MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. |